Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute

doi:10.4251/wjgo.v17.i10.110203

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

(67)

(46)

(0)

(12)

(919)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Oct 15, 2025; 17(10): 110203
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.110203

Table 5 Systemic treatment, n (%)

Variables	n = 52
First-line chemotherapy
Yes	20 (38.5)
No	32 (61.5)
First chemotherapy scheme, n = 20
TEMCAP	16 (80.0)
Cisplatin/etoposide	3 (15.0)
Octreotide	1 (5.0)
Cycles of the 1^st chemotherapy, n = 20
Median (IQR)	9.5 (5.5-20)
Duration of the 1^st chemotherapy, n = 20
Median (IQR)	11 (6-18)
Unregistered	1
Response to the 1^st chemotherapy, n = 20
CR	1 (5.0)
SD	6 (30.0)
PD	10 (50.0)
Not evaluated	3 (15.0)
Second-line chemotherapy, n = 20
Yes	9 (45.0)
No	11 (55.0)
2^nd Chemotherapy scheme, n = 9
CAPOX	2 (22.2)
Dacarbazine	2 (22.2)
TEMCAP	2 (22.2)
Carboplatin/etoposide	1 (11.1)
FOLFOX	1 (11.1)
Interferon alpha	1 (11.1)
2^nd chemotherapy cycles, n = 9
Median (IQR)	3 (2-5)
Duration of the 2^nd chemotherapy, n = 9
Median (IQR)	1 (0-5)
Response to 2^nd chemotherapy, n = 9
CR	1 (11.1)
PR	1 (11.1)
SD	1 (11.1)
PD	4 (44.4)
Not evaluated	2 (22.2)

TEMCAP: Capecitabine plus temozolomide; IQR: Interquartile range; CR: Complete response; SD: Stable disease; PD: Progressive disease; CAPOX: Capecitabine plus oxaliplatin; FOLFOX: Fluorouracil, oxaliplatin, and leucovorin; PR: Partial response.

Full Size Table

Citation: Cruz-Diaz WE, Leonardo A, Saavedra A, Paitan V, Haro-Varas J, Mantilla R, Macetas J, Veramendi E, Pacheco C, Calderón M, Vidaurre T, Castro-Oliden V. Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute. World J Gastrointest Oncol 2025; 17(10): 110203
URL: https://www.wjgnet.com/1948-5204/full/v17/i10/110203.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i10.110203

Cruz-Diaz WE, Leonardo A, Saavedra A, Paitan V, Haro-Varas J, Mantilla R, Macetas J, Veramendi E, Pacheco C, Calderón M, Vidaurre T, Castro-Oliden V. Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute. World J Gastrointest Oncol 2025; 17(10): 110203 [PMID: 41114110 DOI: 10.4251/wjgo.v17.i10.110203]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.